Mercator Launches Trial Of Micro-Infusion Device For Lower-Leg Obstruction

LIMBO-ATX will evaluate adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee were noted in symptomatic patients with critical limb ischemia.

The first patients in the LIMBO-ATX pilot trial of Mercator MedSystems Inc.’s Bullfrog micro-infusion device for the treatment of critical limb ischemia have been enrolled in North Carolina and Texas, Mercator announced July 27.

The trial, planned for 120 patients, is a prospective, 30-center, randomized pilot study of localized adventitial delivery of dexamethasone, an anti-inflammatory corticosteroid, following atherectomy of lesions in arteries below the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

More from Device Area

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By 

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.